China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for HRS-4029. The novel neuroprotective agent will now be assessed in a clinical study as a treatment for acute ischemic stroke (AIS).
Preclinical Findings
Preclinical studies have demonstrated that HRS-4029 can significantly improve neurological function in a rat ischemic stroke model and reduce infarct size. These results suggest the potential for HRS-4029 to become a groundbreaking treatment method for ischemic stroke patients, a population with limited therapeutic options.
Global Innovation
Notably, no similar product has been approved anywhere in the world, positioning HRS-4029 at the forefront of global innovation in stroke treatment. This novel agent represents Hengrui’s commitment to developing cutting-edge therapies to address significant unmet medical needs.-Fineline Info & Tech
Leave a Reply